Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.

@article{Southwood2011DurationOE,
  title={Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.},
  author={T Richard E Southwood and Helen Elisabeth Foster and Joyce E. Davidson and Kimme L Hyrich and Catherine B Cotter and Lucy R Wedderburn and Richard Hull and Helen E. Venning and Joy Rahman and Carole C L Cummins},
  journal={Rheumatology},
  year={2011},
  volume={50 1},
  pages={189-95}
}
OBJECTIVE Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or MTX have been monitored in the British Society for Paediatric and Adolescent Rheumatology Biologics and New Drug Register. Here, we report the duration of etanercept use for the first 5 years of the register and reasons for discontinuation. METHODS Disease subtype and activity, comorbidity, treatment efficacy and safety data were recorded. Etanercept discontinuation was defined as stopping the… CONTINUE READING